Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $46.49 million. The enterprise value is $30.92 million.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 10.80 million shares outstanding. The number of shares has decreased by -0.09% in one year.
Current Share Class | 10.80M |
Shares Outstanding | 10.80M |
Shares Change (YoY) | -0.09% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.42% |
Owned by Institutions (%) | 10.90% |
Float | 8.20M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.62 |
P/TBV Ratio | 3.73 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.01.
Current Ratio | 3.52 |
Quick Ratio | 3.26 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -88.59% and return on invested capital (ROIC) is -58.49%.
Return on Equity (ROE) | -88.59% |
Return on Assets (ROA) | -48.35% |
Return on Invested Capital (ROIC) | -58.49% |
Return on Capital Employed (ROCE) | -163.55% |
Revenue Per Employee | n/a |
Profits Per Employee | -$802,029 |
Employee Count | 24 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.75% in the last 52 weeks. The beta is 1.47, so Lantern Pharma's price volatility has been higher than the market average.
Beta (5Y) | 1.47 |
52-Week Price Change | +14.75% |
50-Day Moving Average | 4.10 |
200-Day Moving Average | 3.79 |
Relative Strength Index (RSI) | 47.78 |
Average Volume (20 Days) | 99,070 |
Short Selling Information
The latest short interest is 523,402, so 4.85% of the outstanding shares have been sold short.
Short Interest | 523,402 |
Short Previous Month | 534,028 |
Short % of Shares Out | 4.85% |
Short % of Float | 6.38% |
Short Ratio (days to cover) | 1.46 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -20.50M |
Pretax Income | -17.75M |
Net Income | -19.25M |
EBITDA | -20.48M |
EBIT | -20.50M |
Earnings Per Share (EPS) | -$1.79 |
Full Income Statement Balance Sheet
The company has $15.90 million in cash and $145,039 in debt, giving a net cash position of $15.76 million or $1.46 per share.
Cash & Cash Equivalents | 15.90M |
Total Debt | 145,039 |
Net Cash | 15.76M |
Net Cash Per Share | $1.46 |
Equity (Book Value) | 12.52M |
Book Value Per Share | 1.16 |
Working Capital | 12.32M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$17.87 million and capital expenditures -$7,270, giving a free cash flow of -$17.87 million.
Operating Cash Flow | -17.87M |
Capital Expenditures | -7,270 |
Free Cash Flow | -17.87M |
FCF Per Share | -$1.66 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Lantern Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 0.09% |
Shareholder Yield | 0.09% |
Earnings Yield | -41.24% |
FCF Yield | -38.29% |
Analyst Forecast
The average price target for Lantern Pharma is $25.00, which is 480.72% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $25.00 |
Price Target Difference | 480.72% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | 3.70% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |